FDA Approves New Triple-Drug Maintenance Treatment for HER2-Positive Breast Cancer

A new treatment option has emerged for people living with advanced HER2-positive breast cancer. The U.S. Food and Drug Administration has approved tucatinib in combination with trastuzumab and pertuzumab as maintenance treatment for eligible adults whose cancer is unresectable locally advanced or metastatic.

HER2-positive breast cancers contain higher levels of the HER2 protein, which can encourage cancer cells to grow more rapidly. Targeted therapies such as trastuzumab and pertuzumab are designed to interfere with this pathway, while tucatinib is a HER2-targeted tyrosine kinase inhibitor.

The development is important because advanced breast cancer generally requires long-term treatment strategies aimed at controlling disease progression and maintaining quality of life.

The approval applies to a specific patient population and treatment setting. It does not mean that the combination is appropriate for every person with breast cancer. Treatment selection depends on cancer subtype, previous therapies, disease progression, overall health and other clinical factors.

The development demonstrates how breast-cancer treatment is increasingly becoming more precisely targeted according to the biological characteristics of individual tumors.